Literature DB >> 23180569

Genetic variation in bone morphogenetic proteins and breast cancer risk in hispanic and non-hispanic white women: The breast cancer health disparities study.

Martha L Slattery1, Esther M John, Gabriela Torres-Mejia, Jennifer S Herrick, Anna R Giuliano, Kathy B Baumgartner, Lisa M Hines, Roger K Wolff.   

Abstract

Bone morphogenetic proteins (BMP) are thought to be important in breast cancer promotion and progression. We evaluated genetic variation in BMP-related genes and breast cancer risk among Hispanic (2,111 cases, 2,597 controls) and non-Hispanic White (NHW) (1,481 cases, 1,586 controls) women who participated in the 4-Corner's Breast Cancer Study, the Mexico Breast Cancer Study and the San Francisco Bay Area Breast Cancer Study. BMP genes and their receptors evaluated include ACVR1, AVCR2A, ACVR2B, ACVRL1, BMP1, BMP2, BMP4, BMP6, BMP7, BMPR1A, BMPR1B, BMPR2, MSTN and GDF10. Additionally, 104 ancestral informative markers were assessed to discriminate between European and native American ancestry. The importance of estrogen on BMP-related associations was suggested through unique associations by menopausal status and estrogen (ER) and progesterone (PR) receptor status of tumors. After adjustment for multiple comparisons ACVR1 (8 SNPs) was modestly associated with ER+PR+ tumors [odds ratios (ORs) between 1.18 and 1.39 padj < 0.05]. ACVR1 (3 SNPs) and BMP4 (3 SNPs) were associated with ER+PR- tumors (ORs 0.59-2.07; padj < 0.05). BMPR2 was associated with ER-PR+ tumors (OR 4.20; 95% CI 1.62, 10.91; padj < 0.05) as was GDF10 (2 SNPs; ORs 3.62 and 3.85; padj < 0.05). After adjustment for multiple comparisons several SNPs remained associated with ER-PR- tumors (padj < 0.05) including ACVR1 BMP4 and GDF10 (ORs between 0.53 and 2.12). Differences in association also were observed by percentage of native ancestry and menopausal status. Results support the hypothesis that genetic variation in BMPs is associated with breast cancer in this admixed population.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180569      PMCID: PMC3653321          DOI: 10.1002/ijc.27960

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix.

Authors:  J Li; L Ji
Journal:  Heredity (Edinb)       Date:  2005-09       Impact factor: 3.821

2.  Genetic ancestry and risk factors for breast cancer among Latinas in the San Francisco Bay Area.

Authors:  Elad Ziv; Esther M John; Shweta Choudhry; Jennifer Kho; Wendy Lorizio; Eliseo J Perez-Stable; Esteban Gonzalez Burchard
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

3.  First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.

Authors:  Mike W Helms; Jens Packeisen; Christian August; Birgit Schittek; Werner Boecker; Burkhard H Brandt; Horst Buerger
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

4.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

Authors:  S G M Piccirillo; B A Reynolds; N Zanetti; G Lamorte; E Binda; G Broggi; H Brem; A Olivi; F Dimeco; A L Vescovi
Journal:  Nature       Date:  2006-12-07       Impact factor: 49.962

5.  Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women.

Authors:  Martha L Slattery; Carol Sweeney; Sandra Edwards; Jennifer Herrick; Kathy Baumgartner; Roger Wolff; Maureen Murtaugh; Richard Baumgartner; Anna Giuliano; Tim Byers
Journal:  Breast Cancer Res Treat       Date:  2007-03       Impact factor: 4.872

6.  Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells.

Authors:  Ming Zhang; Qing Wang; Wei Yuan; Shuang Yang; Xu Wang; Ji-Dong Yan; Jun Du; Jian Yin; Song-Yuan Gao; Bao-Cun Sun; Tian-Hui Zhu
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-16       Impact factor: 4.292

7.  Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation.

Authors:  Mina Takahashi; Fumio Otsuka; Tomoko Miyoshi; Hiroyuki Otani; Junko Goto; Misuzu Yamashita; Toshio Ogura; Hirofumi Makino; Hiroyoshi Doihara
Journal:  J Endocrinol       Date:  2008-09-09       Impact factor: 4.286

8.  Genetic ancestry and risk of breast cancer among U.S. Latinas.

Authors:  Laura Fejerman; Esther M John; Scott Huntsman; Kenny Beckman; Shweta Choudhry; Eliseo Perez-Stable; Esteban González Burchard; Elad Ziv
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 9.  Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review).

Authors:  Lin Ye; Sivan M Bokobza; Wen G Jiang
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

Review 10.  Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells.

Authors:  S G M Piccirillo; A L Vescovi
Journal:  Ernst Schering Found Symp Proc       Date:  2006
View more
  12 in total

1.  MAPK genes interact with diet and lifestyle factors to alter risk of breast cancer: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Abbie Lundgreen; Esther M John; Gabriela Torres-Mejia; Lisa Hines; Anna R Giuliano; Kathy B Baumgartner; Mariana C Stern; Roger K Wolff
Journal:  Nutr Cancer       Date:  2015-01-28       Impact factor: 2.900

2.  Genomic Disparities in Breast Cancer Among Latinas.

Authors:  Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

3.  Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension.

Authors:  François Potus; Michael W Pauciulo; Elina K Cook; Na Zhu; Alexander Hsieh; Carrie L Welch; Yufeng Shen; Lian Tian; Patricia Lima; Jeffrey Mewburn; Christine L D'Arsigny; Katie A Lutz; Anna W Coleman; Rachel Damico; Brooke Snetsinger; Ashley Y Martin; Paul M Hassoun; William C Nichols; Wendy K Chung; Michael J Rauh; Stephen L Archer
Journal:  Circulation       Date:  2020-03-20       Impact factor: 29.690

4.  Genetic variants in anti-Müllerian hormone-related genes and breast cancer risk: results from the AMBER consortium.

Authors:  Hazel B Nichols; Mariaelisa Graff; Jeannette T Bensen; Kathryn L Lunetta; Katie M O'Brien; Melissa A Troester; Lindsay A Williams; Kristin Young; Chi-Chen Hong; Song Yao; Christopher A Haiman; Edward A Ruiz-Narváez; Christine B Ambrosone; Julie R Palmer; Andrew F Olshan
Journal:  Breast Cancer Res Treat       Date:  2020-09-22       Impact factor: 4.872

5.  Basic science and spine literature document bone morphogenetic protein increases cancer risk.

Authors:  Nancy E Epstein
Journal:  Surg Neurol Int       Date:  2014-12-30

6.  Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis.

Authors:  Young Bin Joo; So-Young Bang; Tae-Hwan Kim; Seung-Cheol Shim; Seunghun Lee; Kyung Bin Joo; Jong Heon Kim; Hye Joon Min; Proton Rahman; Robert D Inman
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

7.  GDF10 inhibits proliferation and epithelial-mesenchymal transition in triple-negative breast cancer via upregulation of Smad7.

Authors:  Tian Zhou; Lei Yu; Jianjun Huang; Xueke Zhao; Yanwen Li; Yaxin Hu; Yu Lei
Journal:  Aging (Albany NY)       Date:  2019-05-31       Impact factor: 5.682

8.  TriPOINT: a software tool to prioritize important genes in pathways and their non-coding regulators.

Authors:  Asa Thibodeau; Dong-Guk Shin
Journal:  Bioinformatics       Date:  2019-08-01       Impact factor: 6.937

Review 9.  ACVR1 Function in Health and Disease.

Authors:  José Antonio Valer; Cristina Sánchez-de-Diego; Carolina Pimenta-Lopes; Jose Luis Rosa; Francesc Ventura
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

10.  MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1.

Authors:  Yongxia Wang; Zheying Zhang; Jianqiang Wang
Journal:  Oncol Rep       Date:  2018-04-20       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.